A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison toStandard of Care Therapy in Participants with PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. - Phase II Study of Avelumab+M6620+Carboplatin in PARPi-resistant Ovaria

Merck KGaA0 sites90 target enrollmentSeptember 7, 2018

ConditionsPARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10038977Term: Retroperitoneal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

DrugsBavencio Carboplatin Paclitaxel Avastin 25 mg/ml concentrate for solution for infusion.Gemcitabine

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor: Merck KGaA
Enrollment: 90
Status: Active, not recruiting
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

September 7, 2018

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

Female

Investigators

Sponsor

Merck KGaA

Eligibility Criteria

Inclusion Criteria

•1\. Female participants with recurrent epithelial ovarian cancer who have disease progression following maintenance treatment with a PARPi as defined below:
•1\.1 Participant must have histologically diagnosed epithelial ovarian, primary peritoneal, or fallopian tube cancer, with nonmucinous histology
•1\.2 Participants must have completed at least 2 previous courses of platinum containing therapy (eg, carboplatin or cisplatin) and had documented response (complete response \[CR] or partial response \[PR]) to the last platinum\-based treatment prior to treatment with a PARPi
•1\.3 Participant has received the last dose of platinum\-containing treatment at least 6 months prior to study enrollment
•1\.4 Participant has documented disease progression (radiological) after at least 6 months of maintenance treatment with PARPi following a response to platinum\-based chemotherapy.
•2\. Confirmed BRCA 1/2 mutation status or agree to its testing on samples collected in the study.
•3\. Available formalin\-fixed, paraffin\-embedded (FFPE) tumor biopsies.
•3\.1 Part A: Participant should be willing to undergo 2 paired on\-treatment biopsies on Day 2 of Cycle 1 or Cycle 2, before and after M6620 administration, if assessed as feasible at low risk by the interventional radiologist.
•3\.2 Part B: Histological tissue specimen (tissue block or 8 to 10 unstained slides) must be available. An archival tumor biopsy is acceptable if obtained after the last progression on PARPi treatment and is less than 6 months old. Otherwise, participants must be willing to undergo mandatory biopsy during the Screening Period to obtain sufficient tissue for histological assessment. Participants need to have an attempted biopsy. However, participants who have measurable disease documented by a radiologist as not feasible or safe to be biopsied are eligible to enter the study.
•4\. Measurable disease according to RECIST v1\.1\.

Exclusion Criteria

•1\. Treatment with a nonpermitted drug/intervention as listed below:
•1\.1\. Concurrent anticancer treatment (e.g., cytoreductive therapy, radiotherapy, immune therapy, cytokine therapy, monoclonal antibody, or targeted small molecule therapy) or any study intervention within 4 weeks prior to start of study intervention, or not recovered from AEs related to such therapies
•1\.2\. History of prior dose reductions or dose interruptions while receiving cisplatin or carboplatin due to toxicity from the platinum or intolerance to either agent, unless discussed with and approved by the Sponsor Medical Monitor
•1\.3\. Prior treatment with a PD\-1/PD\-L1 targeting agent
•2\. Current use of the following medications at the time of enrollment:
•2\.1\. Immunotherapy or immunosuppressive drugs at the time of enrollment (e.g., chemotherapy or systemic corticosteroids) EXCEPT for (a) intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra articular injection), (2\) systemic corticosteroids at physiologic doses \= 10 mg/day of prednisone or equivalent, (3\) steroids as premedication for hypersensitivity reactions (e.g., computed tomography \[CT] scan premedication)
•2\.2\. Growth factors EXCEPT where indicated for treatment of study intervention related myelosuppression and for prophylaxis of repeat myelosuppression after initial occurrence
•2\.3\. Herbal remedies with immunostimulating properties (e.g., mistletoe extract) or known to potentially interfere with major organ function (e.g., hypericin)
•2\.4\. Other DNA damage repair inhibitors (except PARPi) (e.g., inhibitors of ATR, ataxia telangiectasia mutated \[ATM] kinase, DNA\-dependent protein kinase \[DNA\-PK], or Wee kinases).